Medical Pharmacology Chapter 6:  Autonomic Pharmacology: Cholinergic Drugs

.

• Overview:  "Cholinergic Drugs - Pharmacology, Animation"

  Attribution:  Alila Medical Media:   Cholinergic Drugs-Pharmacology Animation 6/9/2020. https://www.youtube.com/watch?v=EwsVmTOBZrc https://www.youtube.com/channel/UCiTGKA9W0G0TL8Hm7Uf_u9A

• Location of cholinergic synapses mainly determine the spectrum of action of acetycholine and choline esters.

  • Cholinergic synaptic sites are located:

    • At autonomic effector sites that are innervated by post-ganglionic parasympathetic fibers.

    • At some central nervous system (CNS) synapses.

    • At autonomic ganglia and at the adrenal medulla.

    • at skeletal muscle motor endplates (motor nerves).

• Systemic administration of acetylcholine (ACh) may theoretically act at these sites, but poor CNS penetration and plasma butyrylcholinesterase which hydrolysizes ACh limit systemic effects.

  • ACh is a charged, quaternary nitrogen compound; charged molecules transfer with difficulty across biological membranes.

• Acetylcholine (and other choline esters) effects are initiated by interaction with cholinergic receptors, designated either as muscarinic or nicotinic types.

  • Muscarinic receptors (so defined based of their response to the agent muscarine) are found not only at post-ganglionic parasympathetic effector sites but also at autonomic ganglion cells and adrenal medulla where they modulate nicotinic receptor-mediated effects.

  • Nicotinic receptors are the primary cholinergic receptors at autonomic ganglia and skeletal muscle neuromuscular junctions.

    • These receptors were named because of their responsiveness to the alkaloid nicotine.

• Cholinergic influences are prominent in many organ systems:

1. Modified from Table 7-1: Brown, J.H. and Taylor, P. Muscarinic Receptor Agonists and Antagonists, In, Goodman and Gillman's The Pharmacological Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) The McGraw-Hill Companies, Inc.,1996, p 143

2. Brown, J.H. and Taylor, P. Muscarinic Receptor Agonists and Antagonists, In, Goodman and Gillman's The Pharmacological Basis of Therapeutics,c(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc.,1996, p 142-143.

Disclaimer

This Web-based pharmacology teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.